Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

France drug trial: Three people 'may have irreversible' brain damage after accident

The drug trial involved 90 healthy volunteers

Alexandra Sims
Friday 15 January 2016 17:52 GMT
Comments
Biotrial laboratory building in Rennes where a clinical trial of an oral medication left one person brain-dead and five hospitalised
Biotrial laboratory building in Rennes where a clinical trial of an oral medication left one person brain-dead and five hospitalised (Getty Images)

A botched drug trial in France may have left three people with "irreversible" brain damage, a doctor at the hospital has claimed.

Professor Gilles Edan, the chief neuroscientist at the hospital where the trial took place, said four men have "neurological problems", of whom three could have "irreversible" brain damage, another of the men has been declared brain-dead.

One of the men is being kept in hospital, but is in a less critical condition.

Six previously healthy medical volunteers are now in hospital after taking part in the botched drug test at a private clinic in western France, the Health Ministry said.

The drug trial, which was testing a new painkiller compound, involved 90 healthy volunteers who were given the experimental drug in varying doses, France's health minister Marisol Touraine told a news conference in Rennes.

Professor Edan said there is no known antidote to the experimental drug.

The prosecutor's office has opened an investigation into what Ms Touraine called "an accident of exceptional gravity ... without precedence" in France at the Biotrial lab in Rennes.

The six men in hospital, aged between 28 and 49, were healthy when the trial began on 7 January, Ms Touraine said, adding that one man now classified as brain-dead was admitted to Rennes Hospital on Sunday.

Biotrial, a research company for the reported drug manufacturers, Bial, have defended their drugs safety testing record following the incident.

A spokesperson for Biotrial said it was being conducted in “full compliance with international regulations” and its own procedures, which includes health monitoring.

The drug was based on a natural brain compound similar to the active ingredient in marijuana, Professor Eden confirmed.

Ms Touraine said the medication was not based on cannabis, as some media reports claimed. She urged calm, saying that no drug on the market was implicated in the failed trial. She said the drug was produced by the Portuguese pharmaceutical company Bial.

All the other volunteers are being contacted, Ms Touraine said.

Additional reporting by Press Association

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in